Back

Cost-effectiveness of apixaban vs aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Public health and health economics Health Economics ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Roopinder Sandhu

University of Calgary, Calgary (Canada)

5 More presentations in this session

Presentation thumbnail
Cardiovascular risk factor prevalence, treatment, and control among US adults by income, 2009-2023.
Doctor L. Marinacci (Boston, US)
Abstract Slides Video
Presentation thumbnail
Comparative validation of the AHA PREVENT equation with US and European cardiovascular risk equations among 892,000 adults
Doctor J. Diao (Boston, US)
Abstract Slides Video
Presentation thumbnail
Should body mass index categories differ by ethnicity? All-cause mortality and incident cardiovascular disease in a multi-ethnic cohort of 400,000 adults
Mr C. Li (Auckland, NZ)
Abstract Slides Video
Presentation thumbnail
Impact of abnormal findings in health check-ups on medical care: findings from 15 years of health check-ups
Doctor S. Kameda (Shimotsuke, JP)
Abstract Slides Video
Presentation thumbnail
External validation of the ISARIC-4C mortality risk prediction score in patients hospitalized with COVID-19: Retrospective analysis of the World Heart Federation (WHF) COVID-19 Global Study
Doctor K. Singh (Gurgaon, IN)
Abstract Slides Video

Access the full session

Session thumbnail
Public health and health economics

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Gender and racial differences in outcomes among patients with NVAF treated with oral anticoagulants: a real-world evaluation of Medicare beneficiaries
thumbnail
Congress Presentation
Generic apixaban: how should we buy it at the hospital level?
thumbnail
Congress Presentation
What is the stroke risk threshold for anticoagulation to provide net benefit in atrial fibrillation? A Markov decision model analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources